$0.7308
-0.0592-7.49%
Últ. Act.: Nov 5, 6:32 PM
Metagenomi Therapeutics (MGX) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.54 | $-0.56 | $-0.58 | $-0.56 |
| Actual | $-0.73 | $-0.61 | $-0.60 | $-0.55 |
| Surprise | -35.2% | -8.93% | -3.45% | +1.79% |
| Revenue | ||||
| Estimate | $3.0M | $5.5M | $7.9M | $8.5M |
| Actual | $-257000 | $1.2M | $3.9M | $8.7M |
| Surprise | -108.5% | -77.4% | -50.5% | +2.40% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.64 | $-0.52 | $-0.36 | $-0.38 |
| Revenue | ||||
| Consensus | $2.1M | $2.1M | — | — |
| Trimestre Fiscal | Fecha reportada | EPS real | EPS estimado | Sorpresa % |
|---|---|---|---|---|
| Q2 | Aug 10, 2026 | $-0.73 | $-0.54 | -35.2 % |
| Q1 | May 11, 2026 | $-0.61 | $-0.56 | -8.93 % |
| Q4 | Mar 5, 2026 | $-0.60 | $-0.58 | -3.45 % |
| Q3 | Nov 11, 2025 | $-0.55 | $-0.56 | 1.79 % |
| Trimestre Fiscal | Fecha reportada | Ingresos reales | Ingresos estimados | Sorpresa % |
|---|---|---|---|---|
| Q2 | Aug 10, 2026 | $-257.00K | $3.01M | -108.5 % |
| Q1 | May 11, 2026 | $1.25M | $5.52M | -77.4 % |
| Q4 | Mar 5, 2026 | $3.91M | $7.90M | -50.5 % |
| Q3 | Nov 11, 2025 | $8.66M | $8.46M | 2.40 % |